Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study
- 297 Downloads
Whether antiplatelet agents have a preventive effect on cognitive function remains unknown. We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population. Patients initiating cilostazol therapy between 1 January 2004 and 31 December 2009 without a prior history of dementia were identified from Taiwan's National Health Insurance database. Participants were stratified by age, sex, comorbidities, and comedication. The outcome of interest was all-cause dementia (ICD-9-CM codes 290.0, 290.4, 294.1, 331.0). Cox regression models were used to estimate the hazard ratio (HR) of dementia. The cumulative cilostazol dosage was stratified by quartile of defined daily doses using no cilostazol use as a reference. A total of 9148 participants 40 years of age or older and free of dementia at baseline were analyzed. Patients using cilostazol (n = 2287) had a significantly decreased risk of incident dementia compared with patients not using the drug [n = 6861; adjusted HR (aHR) 0.75; 95% confidence interval (CI) 0.61–0.92]. Notably, cilostazol use was found to have a dose-dependent association with reduced rate of dementia emergence (p for trend = 0.001). Subgroup analysis identified a decline of dementia in cilostazol users with diagnosed ischemic heart disease (aHR 0.44, 95% CI 0.24–0.83) and cerebral vascular disease (aHR 0.34, 95% CI 0.21–0.54). These observations suggest that cilostazol use may reduce the risk to develop dementia, and a high cumulative dose further decreases the risk of dementia. These findings should be examined further in randomized clinical trials.
Key WordsDementia cilostazol cohort studies
This study was supported by grants from Kaohsiung Medical University Hospital (KMUH103-3R68 and KMUH105-5R64), the Ministry of Science and Technology (MOST103-2314-B-037-004-MY3), and Research Center for Environmental Medicine, Kaohsiung Medical University (KMU-TP104A34), none of which have had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors are grateful for the assistance of the Statistical Analysis Laboratory, Department of Medical Research, Kaohsiung Municipal Ta-Tung Hospital.
Required Author Forms
Disclosure forms provided by the authors are available with the online version of this article.
Compliance with Ethical Standards
Conflict of Interest
The authors have no conflict of interest to declare.
- 1.Department of Statistics, Ministry of the Interior, Taiwan, [online]. Available at: http://www.moi.gov.tw/stat/. Accessed January 25, 2017.
- 2.The China Post news staff. Taiwan must address the challenges of an aging society [online]. Available at: http://www.chinapost.com.tw/editorial/taiwan-issues/2013/10/13/391104/Taiwan-must.htm. Accessed October 13, 2013.
- 4.Drugs for Alzheimer's disease: best avoided. No therapeutic advantage. Prescrire international. 2012;21(128):150.Google Scholar
- 5.Birks J, Flicker L. Donepezil for mild cognitive impairment. The Cochrane database of systematic reviews. 2006(3):CD006104.Google Scholar
- 12.WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations [online]. Available at: https://www.whocc.no/ddd/definition_and_general_considera/. Accessed December 20, 2016.
- 16.Wang W, Zhang L, Liu W, Zhu Q, Lan Q, Zhao J. Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2016;25(5):1081–9.CrossRefGoogle Scholar
- 17.Ueda H, Kido A, Matsuhisa S, Asawa K, Yoshida N, Tsujimoto M, et al. Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial. Am Heart J. 2016;173:134–42.CrossRefPubMedGoogle Scholar
- 22.Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2005;25(29):6887–97.CrossRefGoogle Scholar
- 27.ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/show/NCT01409564 (NLM Identifier: NCT01409564). Accessed July 12, 2016.